PR Newswire Europe - AstraZeneca’s Once-Daily SEROQUEL XR(TM) Extended-Release Tablets Approved in Netherlands for the Acute and Long Term Treatment of Schizophrenia.
LONDON, August 29 /PRNewswire/ —
- For International Medical Journalists Only
Most Popular
13 Job Interview Mistakes To Avoid
5 Regular Mistakes In Public Speaking
Public Speaking: 7 Secrets Of Great Public Speakers
10 Jobs That Pay $30 An Hour
3 Questions No Job Seeker Ever Wants To Be Asked?
AstraZeneca today announced the Netherlands regulatory authority MEB (Medicines Evaluation Board) has approved SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in adult patients. With SEROQUEL XR(TM) patients can achieve a dose within the recommended range as early as the second day of treatment and the MEB approval also includes relapse prevention in the long-term treatment of schizophrenia. AstraZeneca will proceed with a Mutual …
Read the rest of this article with a Free Trial at HighBeam Research.
